Vericel Corporation (VCEL)
POSITIVEFundamental
70
Precio
$42.99
Capitalización Bursátil
$2.20B
Parte 1 · Cuánto vale la empresa
Resumen
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$306M
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$24M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$25M
Patrimonio Neto Total
$355M
Pasivo Total
$133M
Ratio de Liquidez
5.04
Cobertura de Intereses
28.49
Deuda/EBITDA
4.12
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$44.40
Precio Actual
$42.99
Margen de Seguridad
+3.2%
Rango de Valor Justo
$30.48 - $58.33
Métodos de Estimación
Métricas de Valoración
Ratio P/E
88.13
ROE
4.7%
Ratio P/B
5.85
P/FCF
35.13
Margen Bruto
74.6%
ROIC
3.2%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
3.2%
WACC
9.8%
ROIC − WACC
-6.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (19)
- EPS shows upward trend
- Price CAGR 30.41%
- Gross Margin 74.6%
- Debt/Equity ratio
- Operating Margin 6.0%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Revenue Growth 5Y 17.3%
- Analyst Consensus 86% Buy
- Earnings Surprise avg 484.8%
- Earnings Quality (OCF/NI) 2.88
- Share Dilution -0.4%
- Net Margin Trend 7.9% vs 2.9%
- Piotroski F-Score 9/9
Fallido (7)
- ROIC 3.2%
- P/FCF 35.13
- P/B Ratio 5.85
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 6.9%
- PEG Ratio 2.40
No disponible (1)
- Dividend Payout NaN%
Piotroski F-Score
Solidez financiera fuerte
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Dominick C. Colangelo Esq. | CEO, President & Director | 61 |
| Mr. Joseph Anthony Mara Jr. | CFO & Treasurer | 49 |
| Mr. Michael Halpin | Chief Operating Officer | 63 |
| Mr. Sean C. Flynn | Chief Legal Officer | 51 |
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer | 63 |
| Mr. Jonathan D. Siegal | Principal Accounting Officer, VP & Corporate Controller | - |
| Mr. Eric Burns | Vice President of Finance & Investor Relations | - |
| Mr. Roland DeAngelis | Chief Marketing Officer | - |
| Mr. Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy | - |
| Mr. Mike Gilligan | Senior Vice President of Sales | - |
Riesgo de Auditoría
4
Riesgo del Consejo
3
Riesgo de Compensación
6
Riesgo de Derechos del Accionista
4
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for VCEL, sourced from Markets Gazette.
- 2/26/2026NEUTRALVericel (VCEL) Q4 2025 Earnings Call Transcript
Biotechnology firm Vericel (VCEL) held its fourth-quarter 2025 earnings conference call. While specific details from the transcript are not yet available, this event is crucial for investors monitoring the company's financial performance and future outlook. Earnings calls are key moments to assess operational health, revenues, profit margins, and management's guidance. The immediate lack of information prevents an in-depth analysis, but the market will keenly await the data release to understand the impact on key products like MACI and Epicel. Investors should remain vigilant for subsequent communications that could influence the stock's valuation.
via Markets Gazette